pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP211057
Phase 3 · small molecule · myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)
APHP211057 for myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD) is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP211057
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)
- Status
- active
- Trials
- 1